Ann Lab Med.  2015 May;35(3):370-372. 10.3343/alm.2015.35.3.370.

A Rare Case of Chronic Myelogenous Leukemia and Plasma Cell Myeloma in the Same Patient

• Ahn S
• Park JS
• Han JH
• Cho SR

• KMID: 2363213
• DOI: http://doi.org/10.3343/alm.2015.35.3.370

Abstract

No abstract available.

MeSH Terms

Aged
Antineoplastic Agents/therapeutic use
Bone Marrow/pathology
Fusion Proteins, bcr-abl/genetics/metabolism
Humans
Imatinib Mesylate/therapeutic use
Leukemia, Myelogenous, Chronic, BCR-ABL Positive/complications/*diagnosis/drug therapy
Leukocyte Count
Male
Multiple Myeloma/complications/*diagnosis/drug therapy
Platelet Count
Polymerase Chain Reaction
Thrombocytosis/etiology
Antineoplastic Agents
Fusion Proteins, bcr-abl
Imatinib Mesylate

Reference

1. Vardiman JW, Melo JV, Baccarani M, Thiele J. Chronic myelogenous leukaemia, BCR-ABL1 positive. In : Swerdlow SH, editor. WHO classification of tumours of haematopoietic and lymphoid tissues. Lyon: IARC;2008. p. 32–37.

2. Hehlmann R, Hochhaus A, Baccarani M. Chronic myeloid leukaemia. Lancet. 2007; 370:342–350. PMID: 17662883.

3. Ide M, Kuwahara N, Matsuishi E, Kimura S, Gondo H. Uncommon case of chronic myeloid leukemia with multiple myeloma. Int J Hematol. 2010; 91:699–704. PMID: 20352382.

4. Alvarez-Larrán A, Rozman M, Cervantes F. Simultaneous occurrence of multiple myeloma and chronic myeloid leukemia. Haematologica. 2001; 86:894. PMID: 11524262.

5. Romanenko NA, Bessmel'tsev SS, Udal'eva Vlu, Zenina MN, Martynkevich IS, Rugal' VI, et al. The combination of chronic myeloid leukemia and multiple myeloma in one patient. Vopr Onkol. 2013; 59:103–110. PMID: 23814859.

6. Pandiella A, Carvajal-Vergara X, Tabera S, Mateo G, Gutiérrez N, San Miguel JF. Imatinib mesylate (STI571) inhibits multiple myeloma cell proliferation and potentiates the effect of common antimyeloma agents. Br J Haematol. 2003; 123:858–868. PMID: 14632777.

7. Pilot PR, Sablinska K, Owen S, Hatfield A. Epidemiological analysis of second primary malignancies in more than 9500 patients treated with imatinib. Leukemia. 2006; 20:148. PMID: 16292349.

8. Verma D, Kantarjian H, Strom SS, Rios MB, Jabbour E, Quintas-Cardama A, et al. Malignancies occurring during therapy with tyrosine kinase inhibitors (TKIs) for chronic myeloid leukemia (CML) and other hematologic malignancies. Blood. 2011; 118:4353–4358. PMID: 21846902.

9. Holmberg M. Is the primary event in radiation-induced chronic myelogenous leukemia the induction of the t(9;22) translocation? Leuk Res. 1992; 16:333–336. PMID: 1564937.